Though both genetic EZH2 suppression and pharmacological EZH2 methyltransferase inhibition lead to NK and T cell activation and enhanced PDAC tumor control following therapy-induced senescence, the anti-tumor effects of small molecule EZH2 inhibition are not as robust or durable as compared with its genetic knockdown. Here, EZH2 is linked to neoplasm.